![Lior Shaltiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 166 600 $ al 30/06/2026
Lior Shaltiel currently works at NurExone Biologic, Inc., as Chief Executive Officer & Director from 2022, NurExone Biologic Ltd., as Chief Executive Officer & Director from 2021, and The Hebrew University of Jerusalem, as Head-BioMed MBA Program from 2015.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC 0,46 % | 27/11/2025 | 425.000 ( 0,46 % ) | 166 600 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Director Ejecutivo | 01/04/2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Director Ejecutivo | 01/04/2021 |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/10/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
NurExone Biologic, Inc.
 NurExone Biologic, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
